These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 10184511)
1. Implications for managed care organizations of the Merck and Medco consent. Pollard MR; Tilson HH Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511 [No Abstract] [Full Text] [Related]
2. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation. Becker S Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588 [No Abstract] [Full Text] [Related]
3. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach. Kuhlik BN Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984 [No Abstract] [Full Text] [Related]
5. Regulating manufacturer-affiliated communication in the information age. Schulman KA; Abernethy DR; Rathore SS; Woosley RL Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664 [No Abstract] [Full Text] [Related]
6. Confidentiality of prescription drug information in the era of computers and managed care. McDonald-Merrill-Ketcham lecture. Lo B Spec Law Dig Health Care Law; 2001 Jun; (266):9-27. PubMed ID: 11434346 [No Abstract] [Full Text] [Related]
7. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003. MacEachern L Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259 [TBL] [Abstract][Full Text] [Related]
8. The response to health care reform by the pharmaceutical industry. Krulwich AS Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983 [No Abstract] [Full Text] [Related]
9. Disease management and antikickback regulations. Kozma CM Manag Care Interface; 2003 Dec; 16(12):34-5. PubMed ID: 14750462 [No Abstract] [Full Text] [Related]
10. Regulatory and legislative challenges facing managed care. Giaquinta D Manag Care Interface; 2000 Jul; 13(7):47-9. PubMed ID: 11183928 [No Abstract] [Full Text] [Related]
11. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach. Mitchell EL Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556 [No Abstract] [Full Text] [Related]
12. Medicare Part D--the product of a broken process. Slaughter LM N Engl J Med; 2006 Jun; 354(22):2314-5. PubMed ID: 16738267 [No Abstract] [Full Text] [Related]
13. Perspectives. Drug formularies pose legal threat to providers. Moskowitz DB Faulkner Grays Med Health; 1995 Feb; 49(6):suppl 1-4. PubMed ID: 10139750 [No Abstract] [Full Text] [Related]
14. How well does your PBM perform? McCarthy R Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211 [No Abstract] [Full Text] [Related]
15. Proposal to regulate formularies draws sharp difference of opinion. Carlson B Manag Care; 2002 Feb; 11(2):34-8. PubMed ID: 11904911 [No Abstract] [Full Text] [Related]
16. PBMs and a Medicare prescription drug benefit. Cohen JP Food Drug Law J; 2000; 55(3):311-20. PubMed ID: 11824463 [No Abstract] [Full Text] [Related]
17. Ghostwriting at elite academic medical centers in the United States. Lacasse JR; Leo J PLoS Med; 2010 Feb; 7(2):e1000230. PubMed ID: 20126384 [TBL] [Abstract][Full Text] [Related]
19. The effect of pharmaceutical benefits managers: is it being evaluated? Schulman KA; Rubenstein LE; Abernethy DR; Seils DM; Sulmasy DP Ann Intern Med; 1996 May; 124(10):906-13. PubMed ID: 8610921 [TBL] [Abstract][Full Text] [Related]
20. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs. Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334 [No Abstract] [Full Text] [Related] [Next] [New Search]